Efficacy of Qizhu Bishi Granules combined with methotrexate in treatment of patients with rheumatoid arthritis

CHEN Chen; LI Yufu; KONG Lingshuang; AN Xiaobei

doi:10.7619/jcmp.20242783

Journal of Clinical Medicine in Practice > 2024 > 28(24): 88-92. > DOI: 10.7619/jcmp.20242783

CHEN Chen, LI Yufu, KONG Lingshuang, AN Xiaobei. Efficacy of Qizhu Bishi Granules combined with methotrexate in treatment of patients with rheumatoid arthritis[J]. Journal of Clinical Medicine in Practice, 2024, 28(24): 88-92. DOI: 10.7619/jcmp.20242783

Citation:

PDF (728 KB)

Efficacy of Qizhu Bishi Granules combined with methotrexate in treatment of patients with rheumatoid arthritis

1.
Department of Rheumatology and Immunology, Shijiazhuang City Third Hospital of Hebei Province, Shijiazhuang, Hebei, 050000
2.
Orthopedic Department of Traditional Chinese Medicine, Shijiazhuang City Third Hospital of Hebei Province, Shijiazhuang, Hebei, 050000

More Information

Received Date: June 30, 2024
Revised Date: September 01, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the efficacy of Qizhu Bishi Granules combined with methotrexate in the treatment of patients with rheumatoid arthritis (RA).
Methods
A total of 140 RA patients in the Shijiazhuang City Third Hospital from January to May 2023 were selected as research objects and randomly divided into a treatment group and a control group, with 70 cases in eachgroup. The control group was treated with methotrexate, while the treatment group was treated with Qizhu Bishi Granules combined with methotrexate, and the treatment duration was 3 months for both groups. The total effective rate, score of traditional Chinese medicine (TCM) syndromes, the number of swollen joints, the number of tender joints, the Visual Analogue Scale (VAS) score for pain, the Disease Activity Score in 28 Joints (DAS28), interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), erythrocyte sedimentation rate (ESR), high-sensitivity C reactive protein (hs-CRP), rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP antibody) levels before treatment and at 1 month and 3 months after treatment as well as therapeutic safety were compared between the two groups.
Results
The total effective rate in the treatment group was 97.14%, which was significantly higher than 87.14% in the control group (P < 0.05). After 1 month and 3 months of treatment, the scores of TCM syndromes, the number of swollen joints, the number of tender joints, the VAS score, DAS28, IL-1, TNF-α, ESR, hs-CRP, RF and anti-CCP antibody levels in the treatment group were significantly lower than those in the control group (P < 0.05). No adverse reactions occurred in both group.
Conclusion
Qizhu Bishi Granules combined with methotrexate in treating RA can effectively alleviate clinical symptoms, improve TCM syndromes, reduce inflammatory responses, decrease disease activity, and the therapeutic efficacy is reliable and safe.
- Qizhu Bishi Granules,
- methotrexate,
- rheumatoid arthritis,
- rheumatoid factors,
- anti-cyclic citrullinated peptide antibody

FullText(HTML)

References (25)

References

[1]	李晓军, 马芹, 张同桐. 血清血管紧张素原和淀粉样蛋白4在类风湿关节炎患者中的表达水平及临床意义[J]. 实用临床医药杂志, 2023, 27(21): 37-41. doi: 10.7619/jcmp.20232131
[2]	戴冰冰, 刘佳丽, 李宁宁, 等. 托法替布治疗难治性中重度类风湿关节炎的疗效及安全性[J]. 实用临床医药杂志, 2022, 26(11): 122-126. doi: 10.7619/jcmp.20214328
[3]	HAAS J P, WEIMANN V, FEIST E. Polyarticular juvenile idiopathic arthritis and rheumatoid arthritis: common features and differences[J]. Z Rheumatol, 2022, 81(1): 4-13. doi: 10.1007/s00393-021-01114-z
[4]	DOUBEK J G C, KAHLOW B S, NISIHARA R, et al. Rheumatoid arthritis and nutritional profile: a study in Brazilian females[J]. Int J Rheum Dis, 2022, 25(10): 1145-1151. doi: 10.1111/1756-185X.14394
[5]	PRASAD P, VERMA S, SURBHI, et al. Rheumatoid arthritis: advances in treatment strategies[J]. Mol Cell Biochem, 2023, 478(1): 69-88. doi: 10.1007/s11010-022-04492-3
[6]	SMOLEN J S, LANDEWÉ R B M, BIJLSMA J W J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update[J]. Ann Rheum Dis, 2020, 79(6): 685-699. doi: 10.1136/annrheumdis-2019-216655
[7]	罗寰, 张霞, 冯娅娆, 等. 中西医结合治疗湿热阻络型类风湿性关节炎患者的疗效观察[J]. 世界中西医结合杂志, 2022, 17(11): 2273-2277.
[8]	中华医学会风湿病学分会. 类风湿关节炎诊断及治疗指南[J]. 中华风湿病学杂志, 2010, 14(4): 265-270.
[9]	ARNETT F C. The 1987 revised ARA criteria for rheumatoid arthritis[J]. Arthritis Rheum, 1987, 30: S17.
[10]	中华中医药学会风湿病分会. 类风湿关节炎病证结合诊疗指南[J]. 中医杂志, 2018, 59(20): 1794-1800.
[11]	HE S H, RENNE A, ARGANDYKOV D, et al. Comparison of an emoji-based visual analog scale with a numeric rating scale for pain assessment[J]. JAMA, 2022, 328(2): 208-209.
[12]	PINCUS T. HAQ and DAS28 for clinical trials over months and MDHAQ, RheuMetric and psycho-socio-economic measures for long-term observations over years?[J]. Rheumatology, 2022, 61(10): 3884-3886.
[13]	JANSEN G, DE ROTTE M C F J, DE JONGE R. Smoking and methotrexate inefficacy in rheumatoid arthritis: what about underlying molecular mechanisms?[J]. J Rheumatol, 2021, 48(10): 1495-1497.
[14]	DAI L Y, ZHAO J X. Re-recognition of methotrexate monotherapy in rheumatoid arthritis[J]. Zhonghua Yi Xue Za Zhi, 2022, 102(37): 2909-2913.
[15]	WESTHOVENS R, RIGBY W F C, VAN DER HEIJDE D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial[J]. Ann Rheum Dis, 2021, 80(6): 727-738.
[16]	MAEDA K, YOSHIDA K, NISHIZAWA T, et al. Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments[J]. Int J Mol Sci, 2022, 23(5): 2871.
[17]	AVOUAC J, PEZET S, VANDEBEUQUE E, et al. Semaphorins: from angiogenesis to inflammation in rheumatoid arthritis[J]. Arthritis Rheumatol, 2021, 73(9): 1579-1588.
[18]	何晓丽, 钟先锦, 龚菊梅, 等. 桔梗总皂苷对胶原性关节炎大鼠的抗炎作用及对TLR/MyD88/NF-κB通路的影响[J]. 中国免疫学杂志, 2021, 37(8): 931-935.
[19]	朱玉光, 方丽佳, 黄素玲. 可溶性α-烯醇化酶由CD14依赖性TLR4信号通路激活单核细胞并影响类风湿关节炎进展的机制[J]. 河北医药, 2023, 45(7): 997-1001.
[20]	孙琳茜, 王子叶, 王丽芹, 等. 靶向IL-6慢病毒介导RNA干扰实验性基因治疗类风湿关节炎[J]. 中国免疫学杂志, 2022, 38(6): 649-655, 660.
[21]	UDA H, EBISU R, MAEDA K, et al. Discrepancy between SAA and CRP levels linked to the difference of SAA/CRP ratio in the patients with early rheumatoid arthritis[J]. Mod Rheumatol, 2022, 32(6): 1035-1040.
[22]	LIU S S, LI J, LI Y S, et al. Correlation of CRP genotypes with serum CRP levels and the risk of rheumatoid arthritis in Chinese Han population[J]. Clin Rheumatol, 2022, 41(11): 3325-3330.
[23]	PERTSINIDOU E, MANIVEL V A, WESTERLIND H, et al. Rheumatoid arthritis autoantibodies and their association with age and sex[J]. Clin Exp Rheumatol, 2021, 39(4): 879-882.
[24]	ABDELHAFIZ D, BAKER T, GLASCOW D A, et al. Biomarkers for the diagnosis and treatment of rheumatoid arthritis - a systematic review[J]. Postgrad Med, 2023, 135(3): 214-223.
[25]	张磊, 王海腾, 严红武, 等. 祛风止痛胶囊联合硫酸羟氯喹治疗类风湿性关节炎的临床研究[J]. 现代药物与临床, 2023, 38(8): 2046-2050.

Cited By

Get Citation

PDF

XML

Article views (37) PDF downloads (2)

Turn off MathJax

Article Contents

Abstract

References

Efficacy of Qizhu Bishi Granules combined with methotrexate in treatment of patients with rheumatoid arthritis

Abstract

References

Catalog

Export File

Citation

Format

Content